I'm sure Novo Nordisk would survive even with slightly lower margins.

Also what proportion of that $1,000 goes to the manufacturer? From what I understand various middlemen and such get a significant proportion of that without providing any value?

e.g. https://www.ftc.gov/news-events/news/press-releases/2024/09/...